[MDS & CMML: Diagnostic and classification]

Orianne Wagner-Ballon; Olivier Kosmider

doi:10.1016/j.bulcan.2023.02.030

[MDS & CMML: Diagnostic and classification]

Bull Cancer. 2023 Nov;110(11):1106-1115. doi: 10.1016/j.bulcan.2023.02.030. Epub 2023 Jul 13.

[Article in French]

Authors

Orianne Wagner-Ballon¹, Olivier Kosmider²

Affiliations

¹ Université Paris Est Créteil, Inserm, IMRB, 94010 Créteil, France; AP-HP, hôpital Henri-Mondor, département d'hématologie et immunologie, 94010 Créteil, France.
² AP-HP, hôpital Cochin, hématologie biologique, Paris, France. Electronic address: [email protected].

PMID: 37453834
DOI: 10.1016/j.bulcan.2023.02.030

Abstract

In 2023, a diagnosis process of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) is mainly based on morphological results obtained on bone marrow and blood smears which could be completed by cytogenetical analyses. Due to recent finding, flow cytometry data are recognized as useful for the diagnosis of CMML especially. Actual classifications and prognostic scoring systems have changed and nowadays include results of high-throughput sequencing approaches in addition to cytogenetical results. All together, these data allow the medical world to correctly evaluate the prognosis of these patients and to provide some information for targeted therapies. This chapter will provide the most important modifications recently published in the field of diagnosis and prognosis of MDS and CMML.

Keywords: CMML; Classification; Diagnosis; Diagnostic; LMMC; MDS; SMD.

Publication types

English Abstract
Review

MeSH terms

Bone Marrow
Humans
Leukemia, Myelomonocytic, Chronic* / diagnosis
Leukemia, Myelomonocytic, Chronic* / genetics
Leukemia, Myelomonocytic, Chronic* / therapy
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / genetics
Prognosis